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In 1995, it is estimated that 17 700 women of a total population of
14.9 million Canadian women were diagnosed with breast cancer,
a 15% increase over the 15 455 cases diagnosed in 1993 (Statistics
Canada, 1995; National Cancer Institute of Canada, 1998). This is
more than twice the estimated number of cases of female lung
(7300) or colorectal (7500) cancer, the next two most common
cancers for Canadian women (National Cancer Institute of
Canada, 1995). As breast cancer is the major malignancy affecting
women, and therefore, a serious health care problem in Canada, it
was thought useful to determine the resources used in breast
cancer management (Will et al, 1993), based on the incidence of
the disease, its management by stage over time, and the costs of
the components of care. As breast cancer is a chronic, systemic
disease (Tabar et al, 1992), a full understanding of resource
consumption must consider the therapeutic options at first diag-
nosis, as well as the management of recurrent or metastatic
disease, and of terminal care.
This paper summarizes the principal costs associated with the
initial treatment of the nonmetastatic stages of this disease in
Canada. We have excluded from this report the 6% of cases that
present with Stage IV disease, because of the multiplicity of
approaches used to treat this group of patients. A subsequent
report will provide estimates of the costs of treating recurrent and
metastatic disease, including Stage IV disease at diagnosis, and a
summation of the lifetime costs of treating breast cancer.
METHODS
Assumptions concerning the breast cancer cost
analysis
A realistic evaluation of the diagnosis and management of a partic-
ular disease requires a number of simplifying assumptions. These
assumptions are that: all patients in Canada have equal access to
diagnosis and treatment; only diagnostic tests essential to the diag-
nosis of breast cancer are included and treatment patterns are
representative of current ‘standard’ Canadian practice. Because
the length of hospital stay is calculated to include all hospitaliza-
tion up to 30 days before and 60 days after surgical intervention,
the cost of important surgical complications is included. We have
also estimated the frequency and cost of hospitalizations related to
chemotherapy. The inclusion of hospital-related complications
will capture most of the costs of treatment-related toxicities.
Our analysis includes only female breast cancers which are
invasive (not in situ) and assumes that there are no major differ-
ences in the therapeutic approaches used for different tumour
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histologies (i.e. ductal and lobular carcinomas follow the same
treatment algorithms). In addition, it is assumed that all surgical
procedures (except for biopsies) are performed on an in-patient
basis, to reflect standard practice in Canada in 1995. As a review
of the national person-oriented database of hospital discharges
(POD) indicated that breast reconstruction was performed infre-
quently (74 procedures for 14 000 women), it is not considered in
this model, nor is the cost of care for patients entered into clinical
trials (Statistics Canada, 1993–1994). Only the costs of initial
management are included, which means any therapy that was
initiated within the first 3 months following the diagnosis of breast
cancer. Finally, the study incorporates only the direct costs associ-
ated with breast cancer management. It does not include indirect
costs, such as the costs of home care, prostheses, travel and
accommodation, care-givers in the home, or lost wages.
Data sources
Many databases and registries were accessed in order to perform
the breast cancer study. The Canadian Cancer Registry (CCR) at
Statistics Canada was used to obtain an estimate of the incidence of
Canadian women diagnosed with breast cancer in 1995. Surveys
were sent to Canadian medical, surgical and radiation oncologists
to determine current diagnostic, staging, therapeutic and follow-up
practice patterns for Stage I, II and III breast cancer patients. The
details of the methodology used to determine Canadian practice are
described elsewhere (Tomiak et al, 1998). Survey results were used
to augment or corroborate existing national databases.
Diagnostic, staging, treatment and survival data were obtained
from several Canadian provincial breast cancer registries,
including the Northern Alberta Breast Cancer Registry (1971–
1988), the Saskatchewan Cancer Foundation (1985–1992), the
British Columbia Cancer Agency (1989–1994), as well as a
special staging study by the Manitoba Cancer Treatment and
Research Foundation and the Manitoba Medical Services
Foundation of all breast cancer cases diagnosed in 1990 (Sloan
and Nemecek, 1995). Saskatchewan Cancer Foundation charts
were retrospectively reviewed to determine current (1993) diag-
nostic approaches and survival, as well as the management of early
stage, recurrent and metastatic disease.
For breast cancer, therapeutic options are dependent upon the
stage of the disease at presentation, the age and menopausal status
of the patient, and the hormone-receptor status of the tumour.
Information regarding the tumour’s hormone receptor status or the
patient’s menopausal status are not routinely available from our
provincial data sources. As a result, the derived treatment algo-
rithms are based upon the woman’s age at the time of diagnosis
(less than 50; or age 50 and over).
Statistics Canada’s national person-oriented database of hospital
discharges (POD), which includes files from April 1993 to March
1994, was used to verify the proportions of women receiving
various surgical procedures, as well as the duration of hospitaliza-
tion for these procedures and for terminal care (Statistics Canada,
1993–94). In order to include any hospitalization for preoperative
tests and procedures, and to incorporate readmissions associated
with surgical complications, all hospital admissions up to 30 days
prior to, and 60 days after the admission date for surgery, were
included in the length of stay calculations. Finally, many breast
cancer specialists gave freely of their time to provide information,
advice and expertise to verify the appropriateness of the breast
cancer model in the Canadian health care environment.
Cost assessment
All costs were determined in constant 1995 Canadian dollars and
the economic analysis was carried out from the perspective of the
government as payer in a universal health care system. As fee
codes and amounts paid for surgical, laboratory and other pro-
cedures are different for each province in Canada, the Canadian
Institute for Health Information (CIHI) was commissioned to
perform a 10-province comparison of the cost of the most
commonly used breast cancer tests and surgical procedures.
Ultimately, the rates in the 1995 Ontario Health Insurance Plan
(OHIP) were used, because they were determined to approximate
closely the average cost of physician assessments, tests and
surgical procedures in Canada.
In order to determine hospital resource utilization by case mix
grouping (CMG), information was obtained from the Ontario Case
Cost Project’s (OCCP) 1993–1995 database for total mastectomy
(CMG 429, 430 and 431) and partial or subtotal mastectomy
(CMG 432 and 433). The OCCP uses standardized methodology
to collect patient-level cost data from 13 Ontario hospitals.
Weighted averages were calculated for women receiving the two
main surgical options, according to age group (< 50 years; ³ 50
years) to arrive at an appropriate per diem rate for each procedure.
The cost of chemotherapy administration included the 1995
chemotherapy and antiemetic drug acquisition costs, the cost of
drug preparation and administration by pharmacy and nursing
personnel (Ottawa Regional Cancer Centre), the laboratory inves-
tigations necessary to monitor patients during chemotherapy, and
physicians’ services and clinic overhead costs, assuming that
chemotherapy was administered on an out-patient basis. Protocols
from the National Surgical Adjuvant Breast and Bowel Project
(NSABP) were reviewed to determine that febrile neutropenia and
dehydration from vomiting were the major complications of
chemotherapy administration likely to require hospitalization for
treatment (NSABP Progress Report, June 1994). The amount of
hospitalization that could result from these chemotherapy compli-
cations was extracted from Statistics Canada’s POD. The hospital
per diem rates were provided by OCCP. These calculations have
been incorporated into the model.
The cost of one fraction of radiotherapy was based on a study
performed at the Ottawa Regional Cancer Centre, based upon
1995/96 costs. The average cost per fraction of radiation therapy
of $138 Canadian included the salaries and benefits of all staff
involved in the radiation treatment programme, as well as the
depreciation of radiotherapy equipment, the capital cost of the
construction of the radiation treatment facilities and administrative
costs (Earle et al, 1997).
Facility overhead costs for ambulatory visits to a cancer centre
to receive radiotherapy or chemotherapy were extracted from
an economic analysis of a National Cancer Institute of Canada
clinical trial (BR-5) (Jaakkimainen et al, 1990). The cost per clinic
visit for a chemotherapy or radiotherapy assessment was adjusted
from $53.11 in 1984 to $76.74 in 1995, based on the increase in
the CPI over that time frame. A 1996 unpublished study shows
similar clinic costs for chemotherapy administration in Ontario (an
average cost per visit of $65.50 compared to our cost of $76.74;
Maroun, 1998). When these more recent data are published, they
will be incorporated into our model.
The costs associated with tamoxifen hormonal therapy were
obtained from the pharmacy departments of the Ottawa Civic and
General hospitals. It was assumed that 20 mg of Tamoxifen would1430 BP Will et al
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be administered daily over a period of 5 years to women requiring
adjuvant hormonal therapy. For this paper on the economic burden
of initial therapy, the cost of providing hormonal therapy is based
on the first year costs only.
RESULTS
According to data from the Canadian province of Saskatchewan,
46% of patients present with Stage I breast cancer and 41% have
Stage II disease. Only 7% and 6% present with Stages III and IV,
respectively. These data are consistent with 1992 Surveillance,
Epidemiology and End Results Program (SEER) data, which indi-
cate that 88.6% of all invasive breast cancer is diagnosed at Stages
I and II, 6.8% at Stage III and 4.6% at Stage IV (Ries et al, 1997).
Canadian Cancer Registry data indicate that 77% of breast cancer
patients are diagnosed at age 50 or older, and that over 60% of
these are between the ages of 60 and 79. Fewer than 6% of women
are diagnosed with breast cancer before they reach the age of 40
(National Cancer Institute of Canada, 1997).
For ease of analysis and presentation, the management of breast
cancer has been divided into modules for diagnosis, staging and
treatment. There are six therapeutic algorithms: one for women
less than 50 years of age at the time of diagnosis, and one for
women aged 50 and over, for each of the three stages. It is assumed
that each component of each treatment algorithm is self-contained
and can be added to other components as the patient progresses
through the course of her illness.
Diagnostic module
The diagnostic module is based upon the results of surveys of
oncologists, the Saskatchewan chart reviews, and informal input
from oncologists. It includes those tests, procedures and assess-
ments required to confirm a diagnosis of breast cancer (see Figure
1). The diagnostic module contains the assumption that a breast
mass that is less than 1 cm in size (pathologically) is considered to
be nonpalpable. The women who present with a nonpalpable
mammographic breast abnormality (approximately 20% of cases)
generally have their diagnosis established by means of a guide
wire localization and biopsy. The majority (80%) of women
present with a palpable breast mass and have the diagnosis of
cancer confirmed with a fine needle biopsy.
Data indicate that a family physician completes the diagnostic
work-up by ordering a chest X-ray, routine blood work and
biochemistry tests, prior to referring the patient for a surgical
consultation. Postmenopausal women also have an ECG as part
of their preoperative work-up. Information taken from cancer
registries and expert opinions indicates that of the 80% of women
diagnosed with a palpable breast mass, all have a bilateral diag-
nostic mammogram, 10% of these women have coneo down
magnification views and 30% have a breast ultrasound. The
majority of women with a palpable mass have a fine needle biopsy.
The average of the diagnostic work-up for a woman presenting
with a palpable mass is $317. Nonpalpable breast abnormalities
discovered by bilateral screening mammography usually require
coneo down magnification views (75% of cases). It is assumed that
all of these are referred for a surgical consultation and are diag-
nosed by means of a guide wire localization and excisional biopsy,
at a total cost of $377.
Staging assessments
All patients undergo preoperative testing and limited staging
investigations. These investigations include a chest X-ray, basic
blood work and biochemistry, in addition to the tests and pro-
cedures included in the diagnostic work-up. Twenty-five per cent
of clinical Stage I and 75% of Stage II patients also have bone
scans and abdominal ultrasounds. All Stage III patients have these
staging studies. Only 5% of Stages I and II have skeletal surveys,
compared with 25% of Stage III. As a result, the average cost of
the staging assessment is estimated to be $142 for Stage I patients,
$257 for Stage II, and $334 for Stage III.
Therapeutic approaches
Surgical options
The treatment algorithms for pre- and postmenopausal patients
with Stages I–III are shown in Figures 2, 3 and 4, respectively.
For Stages I and II, surgery is the treatment of choice, with some
variation in the rate of partial vs total mastectomy according to
stage and age group. For Stage III patients, surgery is employed on
85% of women less than 50 years old and 75% of those age 50
years and older. Of the Stage III patients who undergo surgery,
approximately 15% receive neoadjuvant chemotherapy.
The cost of surgery includes the surgical fee for the procedure,
as well as assistant and anaesthetist fees. Pathology consultation
and technical fees are not included in the cost of surgery, as they
are incorporated into the calculation of hospital resource expendi-
ture. The average cost for breast-conserving surgery (BCS) of
$666 was calculated from the following distribution of procedures,
based on data from Saskatchewan: 20% of women have an
excisional biopsy after a mammographic wire localization; 80%
undergo a partial mastectomy or a wedge resection; 5% of surgical
patients have an anaesthesia consultation; specimen radiography is
done routinely; and all patients undergo axillary node dissection
(AND).
Palpable
Breast Mass
80%
Nonpalpable Breast
Abnormality
20%
Family Doctor Assessment +
Reassessment
Family Doctor Assessment +
Reassessment
Biilateral Diagnostic
Mammogram
Coned Mag Views to 10%
Breast Ultrasound to 30%
Bilateral Screening
Mammogram
Coned Mag views to 75%
Surgical Consultation
Needle Biopsy (FNA)
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Preoperative Tests
Stage-specific
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The cost of a mastectomy was estimated to be $707, based on
the following distribution of surgical procedures, as extracted from
hospital discharge files for 1993–94: 80% of women undergoing a
mastectomy have a modified radical mastectomy; 17% have a
simple mastectomy; and 3% have a radical mastectomy.
Hospitalization
The length of stay for breast-conserving surgery (BCS) for women
less than 50 years old and women aged 50 and over, was 4.5 and
5.2, respectively, compared with 5.6 days and 6.7 days for women
undergoing a mastectomy. It was assumed that one in-patient
physician assessment ($17.10) would be added for each day in
hospital. For those receiving a mastectomy, the average resource
utilization per day for women less than 50 years of age was $741,
compared with $674 for women aged 50 and over. The average
daily resource utilization for all women undergoing partial mastec-
tomies was $838. Combining the per diem rates with length of stay
data, the average total cost of hospitalization for BCS was $3822
for women less than 50 and $4447 for women 50 and over. For
women having a mastectomy, the costs were $4218 and $4643,
respectively.
Radiotherapy costs
Following breast-conserving surgery As indicated in the
algorithms, the majority of women who are treated with breast-
conserving surgery receive postoperative radical radiotherapy. The
Saskatchewan database and the survey results indicate that the
usual dose is 50Gy, which is administered at a rate of five
fractions per week over a 5-week period. It is assumed that
patients receive one initial consultation plus weekly partial
assessments and haematological monitoring during the course of
radiotherapy. Twenty per cent of Stages I and II women and 25%
of Stage III receive a boost dose of 12.5Gy in five fractions. The
total cost of radiotherapy following BCS (including the boost) was
estimated to be $3867 for Stages I and II and $3903 for Stage III.
Diagnosis/Staging
BCS 80/70 Mastectomy 20/30
No Radiotherapy
10/20
Radiotherapy
90/80
Adjuvant Therapy
20/15
No Adjuvant Therapy
80/85
Adjuvant Therapy
30/25
No Adjuvant Therapy
70/75
Hormones
Chemotherapy
Both
25/70
75/20
0/10
Hormones
Chemotherapy
Both
30/80
60/10
10/10
Proportions are shown for women < 50 first, and women ³ 50 after the slash
Figure 2Treatment algorithm for Stage I. Per cent of women aged less than 50/ABE 50 and older (n = 1873/6269)
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Figure 3Treatment algorithm for Stage II. Per cent of women aged less than 50/ABE 50 and older (n = 1669 / 5588)1432 BP Will et al
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Following mastectomy No Stage I patients receive radiotherapy
after mastectomy. However, 15% of Stage II patients receive
postoperative radiotherapy and for Stage III patients, the proportion
is significantly higher (35% of those < 50 years and 50% of those
³ 50 years). The total cost of postoperative radiotherapy, based on
45 Gy administered in five fractions per week over 4 weeks, is
estimated to be $2999.
Chemotherapy costs
The estimates of the proportions of women receiving various
adjuvant chemotherapy regimens (by stage) were based on data
from the Saskatchewan chart reviews and from the survey
responses of oncologists. These data show that when chemo-
therapy is given for early stage breast cancer (Stages I and II), the
majority of patients (70 to 90%) receive six cycles of cyclo-
phosphamide, methotrexate, and 5-fluorouracil (CMF), with a
smaller proportion receiving anthracycline-based regimens [four
cycles of cyclophosphamide and doxorubicin (AC) or six cycles of
cyclophosphamide, doxorubicin and 5-fluorouracil (CAF)]. The
cost of antiemetics has been included in the total cost of
chemotherapy administration. For CMF, the usual antiemetic is
10 mg of oral prochlorperazine, whereas for anthracycline-based
regimens, 8 mg each of oral ondansetron and IV dexamethasone
are administered. In addition, NSABP protocols, the national data-
base of hospital discharges, and OCCP data were used to calculate
the cost of treatment-related toxicities. For 4% of those receiving
CMF and 6.6% of those receiving AC or FAC, we have added 6.0
days of hospitalization at a per diem rate of $595 Canadian to take
into consideration chemotherapy complications such as febrile
neutropenia or dehydration due to vomiting.
In addition to physician assessment fees, blood work and
biochemistry tests, it was assumed that a MUGA scan ($208)
would be required for all women receiving AC and CAF. The
average chemotherapy cost varied from $2376 for Stage I after
BCS, to $2797 for Stage II after mastectomy. There are three
chemotherapy options for Stage III patients: neoadjuvant
chemotherapy, postoperative chemotherapy, and chemotherapy
alone. Six cycles of CAF chemotherapy were identified as the
chemotherapy regimen of choice for all options and were adminis-
tered to 75% of these women at an average cost of $4088.
Cost of hormonal therapy
For those patients receiving hormonal therapy, the cost of 20 mg of
tamoxifen, administered daily over a period of 5 years, with an
annual gynaecological assessment, biochemistry and blood work,
was $427 per year. Because this paper presents only the initial
costs of therapy, we show the cost of providing hormonal therapy
for 1 year, instead of 5 (see Table 1).
Summary of costs by stage and age group
The estimated average costs of diagnosis and initial treatment of
Stages I, II and III breast cancer patients are shown in Table 1. It is
important to note that Table 1 amalgamates the costs of the various
Diagnosis
Staging
Neoadjuvant
Chemotherapy 15/15
No Neoadjuvant
Chemotherapy 85/85
BCS 40/10 Mastectomy 45/65 No Surgery 15/25
Radiotherapy
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65/50
15/55
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treatment arms. As examples, the cost of surgery is a weighted
average of the cost of BCS and mastectomy; the cost of
chemotherapy for Stage III patients combines the costs of
neoadjuvant chemotherapy, postoperative chemotherapy, and
chemotherapy alone. Table 2 provides a detailed breakdown of the
costs of all the tests and procedures for a ‘typical’ breast cancer
case. A Stage 1 postmenopausal woman receiving BCS followed
by radiotherapy (but no adjuvant therapy) was chosen as an
example, as these women represent 35% of all breast cancer cases.
While Table 2 only shows the costs for diagnosis and initial treat-
ment of early stage breast cancer, our comprehensive costing model
for breast cancer will also contain the same level of detail for diag-
nostic and therapeutic options related to all other stages of breast
cancer, as well as for local recurrence and metastatic disease.
The Population Health Model has been used to calculate costs
according to the proportions flowing into each component of the
algorithm (surgery, radiotherapy, chemotherapy, etc.), in order to
arrive at an average total cost for each stage and age group. As
indicated, the total average cost by stage and age group does not
vary a great deal, except that it is slightly more expensive to treat
younger (less than 50 years of age) women, generally because a
higher proportion receive BCS followed by radiotherapy (e.g. for
Stage II women < 50 years old, the total cost is $10 140, compared
with $8048 for women ³ 50 years old).
The largest cost components are hospitalization for surgery,
which ranges from $3458 for Stage III women < 50 years old, to
$4556 for Stage II women ³ 50 years old; and radiotherapy, which
ranges from $1529 for Stage II women ³ 50 years old, to $2768 for
Table 1 Per patient and total costs of diagnosis and initial treatment of breast cancer (1995 Cdn $)
Component
Stage I Stage II Stage III Weighted average
< 50 years ³ 50 years < 50 years ³ 50 years < 50 years ³ 50 years (3 stages)
Diagnosis 329 329 329 329 329 329 329
Staging 142 142 257 257 334 334 206
Surgery 674 678 682 688 589 530 671
Hospitalization 3901 4505 3982 4556 3458 3488 4325
Radiotherapy 2768 2177 2386 1529 2048 1640 2014
Chemotherapy 382 116 2419 446 4091 1529 637
Hormonal therapya 29 68 86 243 47 222 133
Total 8225 8014 10 140 8048 10 897 8073 8315
No. of patientsb 1873 6269 1669 5588 285 954 16 638
Total cost ($,000) 15 403 50 244 16 925 44 970 3105 7701 138 348
aThe cost of hormonal therapy includes therapy provided in the first year only.  bExcludes 1062 patients with Stage IV disease at presentation. Numbers may not
add up due to rounding.
Table 2 Component costs of a ‘typical’ Stage I postmenopausal breast cancer case
Test or procedure Description and costs 1995 costs ($)
Diagnostic Family physician assessment (48.20) and reassessment 353
module (palpable (28.10), mammogram (57.34), breast ultrasound (37.80),
breast mass) surgical consultation (55.90), chest X-ray (30.71), CBC
(10.34), biochemistry I + electrolytes (33.08), fasting blood
sugar (3.10), ECG (15.50), fine needle aspiration (33.40)
Staging Chest X-ray (30.71), CBC (10.34), biochemistry II + 79
assessment electrolytes (38.25)
Surgical Specimen radiography (9.84), partial mastectomy or wedge 674
procedure resection (336.44), radical axillary node dissection (328.12)
(BCS)
Hospitalization $838/day ´ 5.2 days, in-hospital physician assessments 4447
costs (17.10 ´ 5.2 days)
Radiotherapy Radiation consultation (105.40), partial assessment  3653
after BCS (23.10 ´ 5), 25 fractions of radiotherapy (138.00 ´ 25), CBC 
(10.34 ´ 5)
Total 9206
CBC = haemoglobin, differential + platelets. Biochemistry I = alkaline phosphatase, creatinine, SGOT (AST), LDH, bilirubin. Biochemistry
II = alkaline phosphatase, creatinine, SGOT (AST), LDH, bilirubin + calcium. Electrolytes = sodium, potassium + chloride. These costs are
for an individual case and cannot be compared to other costs, which are averages of various therapeutic options.1434 BP Will et al
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Stage I women < 50 years old. Consistent with recent treatment
practices, there are differences in the proportion of patients
receiving systemic adjuvant chemotherapy and hormonal therapy
administered, according to patient age. Chemotherapy is
commonly used for Stage III women less than 50 years old and
costs an average of $4091 per patient, compared with an average
cost of $1529 for those aged ³ 50, who tend to receive more
hormonal therapy. The total estimated cost on a national level for
the initial treatment of Stages I, II and III breast cancer patients is
$65.6, 61.9, and 10.8 million, respectively, differences which are
attributable largely to the proportion of women falling into each of
these stage groups.
DISCUSSION
The breast cancer study has been developed from a number of
comprehensive patient databases, such as the Canadian Cancer
Registry and the national person-oriented database of hospital
discharges. Whenever possible, these databases were compared
with the results of surveys of oncologists and verified by our team
of experts. A review of the reported treatment practices from the
surveys of oncologists suggests that the data provided by the
provincial cancer registries are reasonably representative of
common Canadian treatment practice.
In cases where no national data were available, information
from provincial databases was used, after it was verified. As an
example, the Ontario Fee Schedule was used to determine the costs
of physician assessments, and diagnostic or surgical tests and
procedures. In this case, the Canadian Institute for Health
Information was commissioned to perform comparative provincial
analyses to ensure that these costs were representative of those at
the national level.
It is recognized that there is considerable variation in practice
across the country, stage for stage. For example, a study undertaken
in Ontario found a wide regional variation within the province in
the frequency of breast-conserving surgery (Iscoe et al, 1994).
According to Iscoe and colleagues, the mean proportion of breast-
conserving procedures by county was 52%, with a range from 11 to
84%. This variation was strongly associated with the hospital
where the surgery was performed. Other explanations for the differ-
ences found were the woman’s age at diagnosis (older women were
less likely to undergo BCS) (Silliman et al, 1989; Cady and Stone,
1990; Farrow et al, 1992; Ganz, 1992; Satariano et al, 1992; Howe
et al, 1995), geography (Cady and Stone, 1990; Ferguson et al,
1990; Farrow et al, 1992; Howe et al, 1995), and the availability of
radiotherapy (Cady and Stone, 1990). Also, physician preference
(Cady and Stone, 1990; Long, 1993), tumour size (Delouche et al,
1987; Cady and Stone, 1990; Margolese, 1995), the patient’s own
personal preferences (Cady and Stone, 1990), local medical
customs and practices (Cady and Stone, 1990; Kiebert et al, 1991;
Margolese, 1995), and co-morbidity (Satariano, 1992) all influence
the choice of surgical procedure. Because we were able to use data
on surgical procedures and length of stay from a national database,
the treatment algorithms that we have developed incorporate the
above-mentioned variations in practice patterns and surgical
choices into the national average.
The authors acknowledge that diagnostic tests may be dupli-
cated as patients move through the health care system, or if there
are co-morbid conditions. While this assumption will undoubtedly
lead to undercounting the economic impact of the diagnostic work-
up, these costs are small, and even if doubled, would not constitute
a significant component of the total expenditure on breast cancer.
Surgical treatment-related toxicities and complications during
the initial treatment phase of breast cancer are taken into consider-
ation through the extra days required for hospitalization. Our data
incorporate the costs of immediate postoperative complications, as
well as any readmissions up to 60 days after surgery, but do not
capture out-patient follow-up or home care. This will tend to
underestimate the total initial surgical treatment costs somewhat.
Adjuvant chemotherapy is often associated with acute complica-
tions such as severe nausea and vomiting requiring intravenous
fluid and nutritional support, or, for a small proportion of patients,
febrile neutropenia, which can require hospitalization. The costs
associated with these complications of treatment have been
included in the study.
The surveys of oncologists were used to fill gaps where databases
did not exist. We have had to assume that the oncologists’ question-
naire responses were a true reflection of their practice patterns.
However, it is important to bear in mind that studies have demon-
strated that there is frequently a discrepancy between what physi-
cians claim they do and what they actually do (McPhee et al, 1986;
Sawka et al, 1995). In practice, treatment-related decisions are influ-
enced by a variety of patient characteristics that are not necessarily
incorporated into the scenarios presented in questionnaires.
This analysis could be criticized for including only the direct
medical costs of breast cancer treatment. However, even the
capture and calculation of these costs is a formidable and, at times,
frustrating task, as has been observed by others (Hillner, 1993). In
an attempt to compare our Canadian breast cancer costs with those
of American researchers, we reviewed the work of Baker et al
(1991), Taplin et al (1995) and Riley et al (1995). In all of these
articles, there appears to be consensus that breast cancer costs can
be separated into the cost of initial therapy, ongoing or mainte-
nance care, and terminal care. Direct comparisons of the average
cost of initial therapy for breast cancer patients are problematic as
the length of the ‘initial therapy’ phase can vary from 3 months, as
the comparator years range from 1990 to 1995 and Canadian and
American currencies are used. However, it is interesting to note
that whatever methodology is used, hospitalization consistently
accounts for the bulk of the costs of initial therapy, and Canadian
costs are generally much lower. The average cost of initial therapy
in Canada in 1995 ($8315 Cdn or $6053 US) is considerably less
than the estimates from the above-cited articles. When their costs
are converted to 1995 dollars, they range from $15 536 (Baker et
al, 1991) to $12 424 (Taplin et al, 1995) to $11 792 (Riley et al,
1995). There are two plausible reasons for the difference in costs.
It is generally acknowledged that hospital administration costs in
the United States are higher than those in Canada because of
different health care systems. This is attributed to the fact that
hospitals require large departments to handle the claims of
multiple insurers. As Canadian hospitals are part of a universal
health care system, there is no such requirement. A second reason
could be that the majority of hospitals in the USA are ‘for profit’,
which is not the case in Canada.
Baker and Stommel have both attempted to calculate some of
the indirect costs of cancer care. Baker et al (1991) estimated that
the costs of home care and prescription drugs could increase the
total cost of care by 17% in the USA. Stommel et al (1993) esti-
mated that the average out-of-pocket costs and loss of income
were similar to the costs of a nursing home bed over a 3-month
period ($4563 indirect costs vs $5704 US dollars for a nursing
home). Inclusion of Canadian costs, with appropriate sensitivityDiagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada 1435
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analyses, would give a more comprehensive measure of the full
economic impact of breast cancer. However, the full burden of
breast cancer cannot be determined without also taking into
consideration quality of life issues, which are beyond the scope of
this study.
The breast cancer study has a level of sophistication which, we
believe, provides a realistic ‘baseline’ estimate of the cost per case
of treatment by stage and therapeutic modality. This economic
analysis was conducted as part of a larger effort, to provide infor-
mation on various diseases for a comprehensive microsimulation
model called POHEM (Population Health Model), which is under
development at Statistics Canada. POHEM is designed to simulate
the health status of the Canadian population, by integrating data on
risk factors, disease onset and progression, health care resource
utilization, direct medical care costs and health outcomes
(Wolfson, 1994). POHEM currently models lung cancer and breast
cancer, and contains a simple model of coronary artery disease. A
colorectal cancer module is being developed, as is a more sophisti-
cated cardiovascular disease module.
Models such as POHEM are useful tools to estimate the
economic burden of common disease. For example, the POHEM
lung cancer submodel developed in 1993 allowed us to evaluate
the cost of the diagnosis and treatment of ‘standard’ Canadian
practice, and then to estimate the cost and cost-effectiveness of
several new therapeutic interventions (Evans et al, 1995a, b, 1996;
Evans and Le Chevalier, 1996; Evans, 1996).
We are now completing a study of the therapeutic options for
recurrent and metastatic breast disease. It will then be possible to
estimate the lifetime costs of treating breast cancer in Canada. This
will allow the breast cancer database to be used to assess the cost
impact and cost-effectiveness of new diagnostic, therapeutic or
preventive interventions. For example, it could be used to evaluate
the cost-effectiveness of outpatient breast cancer surgery. Capri
and colleagues found that the cost of the hospital stay for mastec-
tomy in Italy was 40% greater than quadrantectomy, with an
average length of stay which was longer (18 vs 14.1 days) (Capri
et al, 1992). Based on 9 months of data from the 1993–94
Canadian hospital discharge database (10 580 cases), the average
length of stay for mastectomy was also longer than that for BCS
(6.7 days vs 5.2 for women over 50), a 30% difference. There is
clearly a potential to reduce the costs of initial surgical manage-
ment by reducing the number of hospital days in Canada.
McManus and her colleagues analysed 118 patients, all of whom
underwent either modified radical mastectomy, lumpectomy and
axillary node dissection, or axillary dissection alone as outpatients.
They observed only three patients who suffered minor complica-
tions requiring hospital admission. The outpatient cost for
a modified radical mastectomy was $1572 US, compared with an
average 3-day inpatient cost of $6282 US (McManus et al, 1994).
POHEM has been used to show that the adoption of such
approaches in Canada results in significant savings to the health
care system (Evans et al, 1998).
In addition, the breast cancer model could be used to evaluate
new diagnostic approaches such as the cost impact of ‘sentinel’
lymph node biopsy, as suggested by Cady (1996), or stereotactic
core biopsy for nonpalpable mammographic abnormalities.
Hillner suggests that stereotactic core biopsies are less invasive,
avoid anaesthetic risk, cause minimal changes in breast cosmesis
and have a lower initial procedure cost (Hillner, 1996).
Additionally, with the advent of newer, but significantly more
expensive systemic agents (antioestrogens, cytotoxics), the impact
on management costs may be assessed readily. The model is
already being used to evaluate the impact of postmastectomy radi-
ation for patients with node-positive disease, as well as the impact
of hormone replacement therapy on postmenopausal women. Such
information will be invaluable to guide future decisions regarding
treatment policies. The development of models such as this one
will make it possible to assess the interplay between risk factors,
disease states and costs. It provides a valuable tool to measure the
overall health status of Canadians and to analyse the impact of
health policies on the Canadian population.
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